ARIZONA HOUSE OF REPRESENTATIVES

Fifty-sixth Legislature

First Regular Session

 

HB 2486: clinical research; psilocybin; grants; appropriation

Sponsor: Representative Payne, LD 27

Committee on Military Affairs & Public Safety

Overview

Appropriates $30,000,000 from the State General Fund (GF) to the Department of Health Services (DHS) for psilocybin research grants.

History

The Drug Enforcement Administration (DEA) is a United States federal agency under the U.S. Department of Justice that is tasked with enforcing the controlled substances laws of the United States.

Psilocybin is a halogenic chemical obtained from certain types of fresh or dried mushrooms; it is currently a schedule I controlled substance under federal law (DEA Fact Sheet, Psilocybin).

Provisions☐ Prop 105 (45 votes) ☐ Prop 108 (40 votes) ☐ Emergency (40 votes) ☐ Fiscal Note

1.   Appropriates $30,000,000 from the GF in FY 2024 to DHS for psilocybin research grants. (Sec. 3)

2.   Instructs the Director of DHS (Director) to use monies, appropriated to DHS for psilocybin research, for competitive research grants to study whole mushroom psilocybin in phase one, two and three clinical trials. (Sec. 1)

3.   States that the clinical trials are to evaluate the effectiveness of whole mushroom psilocybin in treating various specified mental and physiological disorders. (Sec. 1)

4.   Prioritizes, in the funded clinical trials:

a)   using whole mushroom psilocybin cultivated under a schedule I license issued by the DEA; and

b)   using veterans, first responders, frontline healthcare workers and persons from underserved communities as the research subjects. (Sec. 1)   

5.   Outlines grant application procedures and specifies that grants are to be awarded not later than July 1 of each year for three years. (Sec. 1)

6.   Asserts that those who receive grants and work on whole mushroom psilocybin clinical trials are not to be charged or prosecuted with psilocybin possession in relation to the clinical trial. (Sec. 1)

7.   Establishes the Psilocybin Research Advisory Council (Council) within DHS, consisting of the Director or his designee, and four other members appointed by the Director who meet specified requirements. (Sec. 1)

8.   Directs the Council to:

a)   Establish criteria for the clinical trial research grants;

b)   Oversee the grant application process, review grant applications and assist the Director in selecting the most credible clinical trials to receive grants;

c)   Ensure Council meetings are open to the public and allow public testimony; and

d)   Submit, by July 1 of each year, recommendations on psychedelic-assisted therapy to specified members of the legislative and executive branches. (Sec. 1)

9.   Defines pertinent terms. (Sec. 1)

10.  Repeals this act on January 1, 2029. (Sec. 2)

11.  Exempts monies appropriated for psilocybin research from lapsing until July 1, 2029. (Sec. 3)

 

 

 

 

 

---------- DOCUMENT FOOTER ---------

                        HB 2486

Initials NM       Page 0 Military Affairs & Public Safety

 

---------- DOCUMENT FOOTER ---------